Semaglutide for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 30 Mar 2021: Trial registered, NCT04822181
  2. 1 Apr 2021: Trial started, NCT04822181

The trials

NCT04822181: Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

State
Under way
Phase
Phase 3
People
1,205 taking part
Started
1 Apr 2021
Primary completion
25 Apr 2029
Arms
Semaglutide OW (once weekly )
Results
None posted
  1. 30 Mar 2021: Trial registered
  2. 1 Apr 2021: Trial started

NCT05067621: Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

State
Under way
Phase
Phase 2
People
60 taking part
Started
17 Jul 2023
Primary completion
Dec 2026
Arms
Receive treatment
Results
None posted
  1. 5 Oct 2021: Trial registered
  2. 17 Jul 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.